Navigation Links
Haemacure Achieves Major Milestone - Starts Processing Plasma in Its New Fractionation Facility
Date:6/4/2008

HAE:TSX

MONTREAL, June 4 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX : HAE), a Montreal-based specialty bio-therapeutics company developing high-value human plasma-derived protein products for commercialization, announces that it has started processing plasma in its new fractionation facility for the production of its proprietary all-human fibrin sealant for pivotal Phase II/Phase III clinical trials, leading to commercial launch.

Haemacure has reached an important milestone this week with the commencement of plasma fractionation in its new manufacturing facility. Haemacure also confirms that it is on schedule and on budget to produce clinical material during the third quarter of 2008 and file an amendment to its existing IND with the U.S. Food and Drug Administration during the fourth quarter of 2008, in order to begin clinical trials in the first quarter of 2009.

The new fractionation facility incorporates the Hynetics(R) single-use bio-processing plastic containers technology, which has resulted in significant savings in capital expenditures and will also result in significant savings in operating costs, as compared to a stainless steel facility. The use of this technology also minimizes the risks of cross-contamination between production batches.

"Now that our fractionation facility is operational and that we have started processing plasma, Haemacure is truly engaged in its transformation from a development to a manufacturing company." said Joseph Galli, Chairman and CEO of Haemacure. "The upcoming availability of clinical material will enable Haemacure to pursue its clinical plans in hemostasis and to expand into additional indications, such as adhesion prevention." concluded Mr. Galli.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and develop
'/>"/>

SOURCE HAEMACURE CORPORATION
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Haemacure Reports Third Quarter 2007 Results
2. Haemacure Adopts Strategy for "First-Patient-In" Fibrin Sealant Pivotal Clinical Trials
3. Haemacure announces webcast of presentation at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conferencec
4. Haemacure Announces Details of its Annual General and Special Meeting of Shareholders
5. Media Invitation - Annual General and Special Meeting of Shareholders of Haemacure
6. Haemacure Reports on its annual general and special meeting of shareholders
7. Haemacure Discloses Positive Results of a preclinical study of its fibrin sealant in adhesion prevention and opens a new opportunity in a market with a significant unmet medical need
8. Haemacure to Present at the BioFinance 2008 Conference to be held at the Toronto Marriott Eaton Centre, May 6 - 8, 2008
9. Haemacure financing receives shareholder consent - Series B Warrants are amended
10. Haemacure announces webcast of presentation at Rodman & Renshaw 5th Annual Global Healthcare Conference
11. Haemacure to Present at Busines$ Meets Finance on May 20, 2008 at the Montreal Sheraton Centre
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... have identified new pain relief targets that could ... BBSRC-funded researchers at King,s College London made the ... in the periphery of the body. , Dr ... identifying mechanisms underlying pain generation and our findings ... side effects." , One potential side effect of ...
(Date:4/17/2014)... Two recent papers by a University of ... help scientists develop treatments or vaccines for Dengue ... and other disease-causing flaviviruses. , Jeffrey S. Kieft, ... at the School of Medicine and an early ... and colleagues recently published articles in the scholarly ...
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
(Date:4/17/2014)... (BUSM) have discovered that the anti-seizure drug ezogabine, ... findings, reported in the American Journal of ... more effective treatments for alcoholism. , Excessive consumption ... of illness and death in the U.S. and ... productivity of workers and necessitating huge health care ...
(Date:4/17/2014)... NEW YORK (17 April 2014) Population Council scientists and ... is safe, stable, and can prevent the transmission of ... and rectum in animals: HIV, herpes simplex virus 2 ... provides the first data that the gel is effective ... of efficacy in the vagina against all three viruses ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... Demand for Dark Chocolate by Active, On-the-Go Consumers , , ... Fueled by demand for nutritious, yet delicious snacks, Abbott ... ZonePerfect (R) Dark Chocolate Nutrition Bars - Dark ... Creme. , , Made with real cacao, ZonePerfect ...
... YORK, June 2 , ... 1991 , PharmaPendium ( http://www.info.pharmapendium.com/ ... drug,information, has significantly expanded its coverage of US Food ... the FDA Classic,Collection. This collection contains all available historical ...
... for Focus, Performance and Recovery , , HUNTINGTON BEACH, ... high-performance sports water designed ... to give them an edge, in terms of focus, better ... , , "With AquaHydrate, we believe ...
... be used to perform several screens, researchers say , TUESDAY, ... stool can accurately screen for more types of cancer than ... DNA stool testing has been successfully used for early detection ... that the noninvasive screening is also good at finding other ...
... researchers have demonstrated that a noninvasive screening test can detect ... the colon -- including pancreas, stomach, biliary and esophageal cancers. ... being presented at Digestive Disease Week 2009 in Chicago, May ... for approximately one in four cancer deaths. While high cure ...
... 2 June 2009 -- PharmaPendium ( http://www.info.pharmapendium.com ), ... drug information, has significantly expanded its coverage of US ... launch of the FDA Classic Collection. This collection contains ... including those issued in 1991 all indexed and ...
Cached Medicine News:Health News:Three New ZonePerfect(R) Dark Chocolate Nutrition Bar Flavors Fuel Satisfying and Delicious Snacking 2Health News:Three New ZonePerfect(R) Dark Chocolate Nutrition Bar Flavors Fuel Satisfying and Delicious Snacking 3Health News:Three New ZonePerfect(R) Dark Chocolate Nutrition Bar Flavors Fuel Satisfying and Delicious Snacking 4Health News:Elsevier's PharmaPendium(TM) Introduces the FDA Classic Collection 2Health News:Elsevier's PharmaPendium(TM) Introduces the FDA Classic Collection 3Health News:The First High-Performance Sports Water, AquaHydrate, Delivers Cellular Hydration and Electrolytes, Naturally 2Health News:The First High-Performance Sports Water, AquaHydrate, Delivers Cellular Hydration and Electrolytes, Naturally 3Health News:The First High-Performance Sports Water, AquaHydrate, Delivers Cellular Hydration and Electrolytes, Naturally 4Health News:Simple Test Could Detect More Gastrointestinal Cancers 2Health News:Improved DNA stool test could detect digestive cancers in multiple organs 2Health News:Improved DNA stool test could detect digestive cancers in multiple organs 3Health News:Elsevier's PharmaPendium introduces the FDA Classic Collection 2
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led ... a premier and affordable laser tattoo removal experience with ... Brandeis, focus is in providing high quality cosmetic services with cutting ... " Southern California has seen a ...
(Date:1/14/2014)... , Jan. 14, 2014 NineSigma , Inc., ... its Innovation Leadership Summit , May 14-16, 2014 ... Cleveland Ohio . This ... organizations committed to breakthrough achievements through open innovation. Participants ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... Cardica, Inc. (Nasdaq: CRDC ) today announced ... Proximal Anastomosis System will be featured in several demonstration ... and Hybrid Coronary Revascularization conference, a meeting jointly developed ... Joseph,s Hospital in Atlanta, Georgia. "This ...
... announced that it has received approval from the United ... 7,815,929) regarding a method for the preparation, storage and ... nature, the process of compounding suppositories is cumbersome, time-consuming ... Muni, founder, chairman, and CEO of CutisPharma, Inc. "Our ...
Cached Medicine Technology:Cardica's Automated Anastomosis Systems Featured at Advances In Robotic And Hybrid Coronary Revascularization Meeting 2Cardica's Automated Anastomosis Systems Featured at Advances In Robotic And Hybrid Coronary Revascularization Meeting 3CutisPharma Announces Issuance of an Additional Patent for Suppository Compounding 2
BD Persist Plus protective barrier skin preps with chlorhexidine in alcohol...
... Sterile Isopropyl Alcohol 70% USP and 10% ... as a topical antiseptic, anti-infective prior to ... removal of oils and fats from the ... AAMI/ANSI/ISO 11137 standards to contain a consistent ...
Aplicare's Prep Pads offer convenience, low cost, ease of use. The medium size is appropriate for most applications. Each package is terminally sterilized, ensuring the safest possible product for th...
IV Prep Swab Sticks are effective, easy to apply, dries quickly and reduces bacterial contaminations. They are ideal for preparation of the skin prior to a ventipuncture or injection....
Medicine Products: